Citations

Clear

154 citation(s) found for "Levin, G".

Deciphering the genomic fingerprint of small cell prostate cancer with potential clinical utility.
Alshalalfa, Mohammed , Haddad, Zaid , Ross, Ashley E. , Karnes, R. Jeffrey , Tsai, Harrison , Davicioni, Elai , Schaeffer, Edward M. , Lotan, Tamara Levin

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 2_suppl | Pages: 303-303

10.1200/jco.2016.34.2_suppl.303 Get It

303 Background: Small cell (SC) neuroendocrine carcinoma of the prostate has very poor prognosis and does not respond well to androgen receptor (AR)-targeted therapies. Neuroendocrine prostate carcinomas are increasingly recognized to show a spectrum of morphologic changes, and may not always be distinguishable from adenocarcinoma (adeno) based on morphology alone. Here we hypothesize that SC carcinoma harbor a unique gene expression signature that, when measured in primary prostatic adenocarcinoma, may help guide subsequent management. Methods: In total, 617 whole genome expression profiles were retrieved from the Decipher GRID providing gene expression data for 1.4 million markers. 17 morphologically-diagnosed SC carcinoma samples were compared to 32 Gleason 8-10 and 77 Gleason 6 RP adeno samples with no prior treatment and no evidence of metastasis, and this comparison was used to define SC Genomic Fingerprint (SCGFt) through adjusted median fold difference and Wilcoxon test. An additional 493 RP adeno from Mayo Clinic and John Hopkins Hospital were used to evaluate the utility of the SCGFt for predicting outcome. Results: Based on genomic prognostic tests calculated using the Decipher assay including Decipher, Penney and microarray-derived Cell Cycle Progression, SC carcinomas have very poor prognosis compared to high grade adeno. A total of 356 genes defined the SCGFt with 258 gene upregulated in SC and 98 down-regulated. PEG10, HELLS and RB1-loss program are the most overexpressed genes in SC and AR-related genes the most down-regulated. As expected, SC lacked ERG and alternative ETS expression and showed relatively low SPINK1 expression. A median summarization of the 356 genes in SCGFt was used to build a small cell genomic score (SCGS). Evaluating SCGS in RP adeno cohorts showed that patients with high SCGS are at higher risk of developing metastasis after RP in a natural history cohort or after adjuvant hormonal therapy based on Kaplan Meier analysis (both p< 0.001). When restricted to patients with high Decipher scores, SCGS provided independent prognostic information. Conclusions: SC carcinoma has a distinct genomic profile that may be useful for treatment management of patients with adenocarcinoma.
Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure.
Karnes, Jeffrey , Ashab, Hussam Al-Deen, Ross, Ashley E. , Tosoian, Jeffrey J. , Erho, Nicholas , Choeurng, Voleak, Yousefi, Kasra, Haddad, Zaid , Feng, Felix Y. , Dicker, Adam P. , Jenkins, Robert B. , Trock, Bruce J , Tsai, Harrison , Abdollah, Firas , Klein, Eric A. , Nguyen, Paul L. , Den, Robert B. , Davicioni, Elai , Lotan, Tamara Levin , Schaeffer, Edward M. , Dicker, Adam P

Mayo Clinic

Journal of Clinical Oncology | February 24, 2017 | Volume: 34 | Issue: 2_suppl | Pages: 106-106

10.1200/jco.2016.34.2_suppl.106 Get It

106 Background: Androgen deprivation therapy (ADT) is one of the main treatment options for locally advanced and metastatic prostate cancer. Neuroendocrine prostate cancer (NEPC) is inherently less sensitive or even resistant to ADT. NEPC can be observed de novo (e.g., small cell prostate cancer) but more commonly arises after exposure to ADT. We hypothesized that a gene expression signature of NEPC when measured in primary tumor specimens (RP) of prostatic adenocarcinoma may be useful for predicting patients with innate resistance to ADT. Methods: Expression profiles of 1023 PCa patients treated with RP were obtained from the Decipher GRID database. These were split into training (n=529) and validation (n=494) sets and stratified by the receipt of adjuvant ADT (n=243) or no adjuvant ADT (n=780). A literature review of ADT resistance and neuroendocrine genes identified 1,557 genes as candidates. This set was further filtered, using logistic regression to select a 52-gene ADT resistance signature (ARS). ARS was trained using a generalized linear model with lasso regularization. Survival c-index and Kaplan Meier was used to compare survival differences between treated and untreated patients with high and low ARS scores (defined by median split). Results: In validation cohorts, the ARS was predictive of metastasis in cohorts receiving adjuvant ADT (10-year metastasis free survival c-index of 0.69 (95% CI 0.59-0.78) as compared to 0.45 (95% CI 0.29-0.61) in patients not treated with ADT). Similarly in a separate cohort of untreated patients that received no ADT until after metastatic onset, ARS was not prognostic (c-index 0.53). Among ADT treated patients, those with low ARS scores had a 10 year MFS of 87%, versus 70% in those with high ARS scores (p<0.001). In the subset of men who received ADT after metastatic onset and who developed castrate-resistant prostate cancer (CRPC, n = 41), median time to treatment failure was 1 year in patients with high ARS compared to 2 years for those with low ARS scores (p=0.07). Conclusions: A 52-gene ADT resistance signature was developed which showed significant differences in metastasis-free survival among adjuvant hormone treated but not untreated patients.
Quantitative assessment of lung stiffness in patients with interstitial lung disease using MR elastography
Marinelli, John P. , Levin, David L. , Vassallo, Robert , Carter, Rickey E. , Hubmayr, Rolf D., McGee, Kiaran P. , Ehman, Richard L. , Vassallo, Robert , Carter, Rickey E

Mayo Clinic

Journal of Magnetic Resonance Imaging | January 24, 2017 | Volume: 46 | Issue: 2 | Pages: 365-374

10.1002/jmri.25579 | PMID 28117930 Get It

PurposeTo investigate the use of magnetic resonance elastography (MRE) in the quantitative assessment of pulmonary fibrosis by comparing quantitative shear stiffness measurements of lung parenchyma in patients diagnosed with fibrotic interstitial lung disease (ILD) and healthy controls.Materials and MethodsA 1.5T spin‐echo, echo planar imaging MRE (SE‐EPI MRE) pulse sequence was utilized to assess absolute lung shear stiffness in 15 patients with diagnosed ILD and in 11 healthy controls. Data were collected at residual volume (RV) and total lung capacity (TLC). Spirometry data were obtained immediately prior to scanning. To test for statistical significance between RV and TLC shear stiffness estimates a two‐sample t‐test was performed. To assess variability within individual subject shear stiffness estimates, the intraclass correlation coefficient (ICC) and Krippendorff's alpha were calculated.ResultsPatients with ILD exhibited an average (±1 standard deviation) shear stiffness of 2.74 (±0.896) kPa at TLC and 1.32 (±0.300) kPa at RV. The corresponding values for healthy individuals were 1.33 (±0.195) kPa and 0.849 (±0.250) kPa, respectively. The difference in shear stiffness between RV and TLC was statistically significant (P < 0.001). At TLC, the ICC and alpha values were 0.909 and 0.887, respectively. At RV, the ICC and alpha values were 0.852 and 0.862, respectively.ConclusionIn subjects with known fibrotic interstitial lung disease, parenchymal shear stiffness is increased when compared to normal controls at both RV and TLC, with TLC demonstrating the most significant difference. MRE‐derived parenchymal shear stiffness is a promising new noninvasive imaging‐based biomarker of interstitial lung disease.Level of Evidence: 1Technical Efficacy: Stage 2J. MAGN. RESON. IMAGING 2017;46:365–374
Dose-efficient ultrahigh-resolution scan mode using a photon counting detector computed tomography system
Yu, Zhicong , Halaweish, Ahmed F., Kappler, S. , Hähn, Katharina, Henning, André , Li, Zhoubo , Lane, John I. , Levin, David L. , Jorgensen, Steven M., Ritman, Erik L., Lane, John , Jorgensen, Steven, Ritman, Erik, McCollough, Cynthia, Leng, Shuai , McCollough, Cynthia H. , Leng, Shuai , Kappler, Steffen

Mayo Clinic

Journal of Medical Imaging | December 22, 2016 | Volume: 3 | Issue: 4 | Pages: 043504

10.1117/1.jmi.3.4.043504 | PMID 28042589 Get It

Shifts in the Fecal Microbiota Associated with Adenomatous Polyps
Hale, Vanessa L. , Johnson, Stephen , Harrington, Sean C., Yab, Tracy C. , Smyrk, Thomas C. , Nelson, Heidi , Boardman, Lisa A., Druliner, Brooke R., Levin, Theodore R. , Rex, Douglas K. , Ahnen, Dennis J. , Lance, Peter , Ahlquist, David A. , Chia, Nicholas , Chen, Jun , Boardman, Lisa A., Druliner, Brooke R. , Chia, Nicholas

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 26, 2016 | Volume: 26 | Issue: 1 | Pages: 85-94

10.1158/1055-9965.epi-16-0337 | PMID 27672054 Get It

Abstract Background: Adenomatous polyps are the most common precursor to colorectal cancer, the second leading cause of cancer-related death in the United States. We sought to learn more about early events of carcinogenesis by investigating shifts in the gut microbiota of patients with adenomas. Methods: We analyzed 16S rRNA gene sequences from the fecal microbiota of patients with adenomas (n = 233) and without (n = 547). Results: Multiple taxa were significantly more abundant in patients with adenomas, including Bilophila, Desulfovibrio, proinflammatory bacteria in the genus Mogibacterium, and multiple Bacteroidetes species. Patients without adenomas had greater abundances of Veillonella, Firmicutes (Order Clostridia), and Actinobacteria (family Bifidobacteriales). Our findings were consistent with previously reported shifts in the gut microbiota of colorectal cancer patients. Importantly, the altered adenoma profile is predicted to increase primary and secondary bile acid production, as well as starch, sucrose, lipid, and phenylpropanoid metabolism. Conclusions: These data hint that increased sugar, protein, and lipid metabolism along with increased bile acid production could promote a colonic environment that supports the growth of bile-tolerant microbes such as Bilophilia and Desulfovibrio. In turn, these microbes may produce genotoxic or inflammatory metabolites such as H2S and secondary bile acids, which could play a role in catalyzing adenoma development and eventually colorectal cancer. Impact: This study suggests a plausible biological mechanism to explain the links between shifts in the microbiota and colorectal cancer. This represents a first step toward resolving the complex interactions that shape the adenoma–carcinoma sequence of colorectal cancer and may facilitate personalized therapeutics focused on the microbiota. Cancer Epidemiol Biomarkers Prev; 26(1); 85–94. ©2016 AACR.
Response and Rebuttal to Editorial Commentary on “Erectile and Ejaculatory Function Preserved with Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study”
McVary, Kevin T. , Gange, Steven, Gittelman, Marc , Patel, Kalpesh, Levin, Richard, Rousseau, Michael, Beahrs, J. Randolf, Kaminetsky, Jed , Cowan, Barrett E., Cantrill, Christopher H., Mynderse, Lance A. , Ulchaker, James, Larson, Thayne R., Dixon, Christopher , Roehrborn, Claus G. , Goldberg, Kenneth A. , Shore, Neal D.

Mayo Clinic

The Journal of Sexual Medicine | May 23, 2016 | Volume: 13 | Issue: 6 | Pages: 936-937

10.1016/j.jsxm.2016.05.002 | PMID 27215688 Get It

Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis — United States
Biggs, Holly M. , Behravesh, Casey Barton , Bradley, Kristy, Dahlgren, F. Scott , Drexler, Naomi A. , Dumler, J. Stephen , Folk, Scott M., Kato, Cecilia Y. , Lash, R. Ryan , Levin, Michael L. , Massung, Robert F., Nadelman, Robert B., Nicholson, William L. , Paddock, Christopher D., Pritt, Bobbi S. , Traeger, Marc, Paddock, Christopher D. , Pritt, Bobbi S

Mayo Clinic

MMWR. Recommendations and Reports | May 12, 2016 | Volume: 65 | Issue: 2 | Pages: 1-44

10.15585/mmwr.rr6502a1 | PMID 27172113 Get It

Erectile and Ejaculatory Function Preserved with Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study
McVary, Kevin T. , Gange, Steven, Gittelman, Marc , Patel, Kalpesh, Levin, Richard, Rousseau, Michael, Beahrs, J. Randolf, Kaminetsky, Jed , Cowan, Barrett E., Cantrill, Christopher H., Mynderse, Lance A. , Ulchaker, James, Larson, Thayne R., Dixon, Christopher , Roehrborn, Claus G. , Goldberg, Kenneth A. , Shore, Neal D.

Mayo Clinic

The Journal of Sexual Medicine | April 29, 2016 | Volume: 13 | Issue: 6 | Pages: 924-933

10.1016/j.jsxm.2016.03.372 | PMID 27129767 Get It

ABSTRACT Introduction Most surgical treatments for male lower urinary tract symptoms and benign prostatic hyperplasia affect erectile and ejaculatory functions negatively, leading to patient dissatisfaction. Aim To determine whether water vapor thermal therapy, when conducted in a randomized controlled trial, would significantly improve lower urinary tract symptoms secondary to benign prostatic hyperplasia and urinary flow rate while preserving erectile and ejaculatory functions. Methods Men at least 50 years old with International Prostate Symptom Scores of at least 13, a peak flow rate of at least 5 to no higher than 15 mL/s, and prostate volume of 30 to 80 cm3 were randomized 2:1 between Rezūm System thermal therapy and control. Thermal water vapor (103°C) was injected into lateral and median lobes as required for treatment of benign prostatic hyperplasia. The control procedure entailed rigid cystoscopy with simulated active treatment sounds. Main Outcome Measures Blinded group (active = 136, control = 61) comparison occurred at 3 months and the active arm was followed to 12 months for International Prostate Symptom Score, peak flow rate, and sexual function using the International Index of Erectile Function and the Male Sexual Health Questionnaire for Ejaculatory Function. The minimal clinically important difference in erectile function perceived by subjects as beneficial was determined for each erectile function severity category. Subjects not sexually active were censored from sexual function analysis. Results No treatment- or device-related de novo erectile dysfunction occurred after thermal therapy. International Index of Erectile Function and Male Sexual Health Questionnaire for Ejaculatory Function scores were not different from the control group at 3 months or from baseline at 1 year. Ejaculatory bother score improved 31% over baseline (P = .0011). Also, 32% of subjects achieved minimal clinically important differences in erectile function scores at 3 months, and 27% at 1 year, including those with moderate to severe erectile dysfunction. International Prostate Symptom Score and peak flow rate were significantly superior to controls at 3 months and throughout 1 year (P &lt; .0001). Conclusion Convective water vapor thermal therapy provides sustainable improvements for 12 months to lower urinary tract symptoms and urinary flow while preserving erectile and ejaculatory functions.
Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
McVary, Kevin T. , Gange, Steven, Gittelman, Marc , Patel, Kalpesh, Levin, Richard, Rousseau, Michael, Beahrs, J. Randolf, Kaminetsky, Jed , Cowan, Barrett E., Cantrill, Christopher H., Mynderse, Lance A. , Ulchaker, James, Larson, Thayne R., Dixon, Christopher , Roehrborn, Claus G. , Goldberg, Kenneth A. , Shore, Neal D.

Mayo Clinic

Journal of Urology | November 22, 2015 | Volume: 195 | Issue: 5 | Pages: 1529-1538

10.1016/j.juro.2015.10.181 | PMID 26614889 Get It